early fetal gender determination using real-time pcr analysis of cell-free fetal dna during 6th-10th weeks of gestation.
Authors
abstract
nowadays, new advances in the use of cell free fetal dna (cffdna) in maternal plasma of pregnant women has provided the possibility of applying cffdna in prenatal diagnosis as a non-invasive method. in contrary to the risks of invasive methods that affect both mother and fetus, applying cffdna is proven to be highly effective with lower risk. one of the applications of prenatal diagnosis is fetal gender determination, which is important in fetuses at risk of sex-linked genetic diseases. in such cases by obtaining the basic information of the gender, necessary time management can be taken in therapeutic to significantly reduce the necessity of applying the invasive methods. therefore in this study, the probability of detecting sequences on the human y-chromosome in pregnant women has been evaluated to identify the gender of fetuses. peripheral blood samples were obtained from 80 pregnant women with gestational age between 6th to 10th weeks and the fetal dna was extracted from the plasma. identification of sry, dys14 & daz sequences, which are not presentin the maternal genome, was performed using real-time pcr. all the obtained results were compared with the actual gender of the newborns to calculate the test accuracy. considerable 97.3% sensitivity and 97.3% specificity were obtained in fetal gender determination which is significant in the first trimester of pregnancy. only in one case, false positive result was obtained. using non-invasive method of cffdnas in the shortest time possible, as well as avoiding invasive tests for early determination of fetal gender, provides the opportunity of deciding and employing early treatment for fetuses at risk of genetic diseases.
similar resources
Early fetal gender determination using real-time PCR analysis of cell-free fetal DNA during 6th-10th weeks of gestation.
Nowadays, new advances in the use of cell free fetal DNA (cffDNA) in maternal plasma of pregnant women has provided the possibility of applying cffDNA in prenatal diagnosis as a non-invasive method. In contrary to the risks of invasive methods that affect both mother and fetus, applying cffDNA is proven to be highly effective with lower risk. One of the applications of prenatal diagnosis is fet...
full textfetal sex determination using non-invasive method of cell-free fetal dna in maternal plasma of pregnant women during 6th– 10th weeks of gestation
in previous years, identification of fetal cells in maternal blood circulation has caused a new revolution in non-invasive method of prenatal diagnosis. low number of fetal cells in maternal blood and long-term survival after pregnancy limited the use of fetal cells in diagnostic and clinical applications. with the discovery of cell-free fetal dna (cffdna) in plasma of pregnant women, access to...
full textFetal Sex Determination using Non-Invasive Method of Cell-free Fetal DNA in Maternal Plasma of Pregnant Women During 6th– 10th Weeks of Gestation
In previous years, identification of fetal cells in maternal blood circulation has caused a new revolution in non-invasive method of prenatal diagnosis. Low number of fetal cells in maternal blood and long-term survival after pregnancy limited the use of fetal cells in diagnostic and clinical applications. With the discovery of cell-free fetal DNA (cffDNA) in plasma of pregnant women, access to...
full textFetal RHD Genotyping Using Real-Time Polymerase Chain Reaction Analysis of Cell-Free Fetal DNA in Pregnancy of RhD Negative Women in South of Iran
Objective Maternal-fetal RhD antigen incompatibility causes approximately 50% of clinically significant alloimmunization cases. The routine use of prophylactic anti-D immunoglobulin has dramatically reduced hemolytic disease of the fetus and newborn. Recently, fetal RHD genotyping in RhD negative pregnant women has been suggested for appropriate use of anti-D immunoglobulin antenatal prophylaxi...
full textFetal sex determination using circulating cell-free fetal DNA (ccffDNA) at 11 to 13 weeks of gestation.
OBJECTIVE To examine the performance of a mass spectrometry-based detection platform using three Y-chromosome sequences for fetal sex determination from circulating cell-free fetal DNA (ccffDNA) in maternal blood in the first trimester of pregnancy. METHODS We extracted ccffDNA for the determination of fetal sex from stored maternal plasma obtained at 11 to 13 weeks' gestation from singleton ...
full textReal-Time Quantitative PCR for Detection Cell Free Fetal DNA
Basically, diagnosis inherited diseases in gestation is very important. But amplication of the progress in early stage of pregnance is the serious and great aim for rapid application of risk assesment for both and fetus. Fetal genetic tissues collected through techniques such as amniocentesis and chorionic villus sampling (CVS) for prenatal diagnosis of fetal genetic diseases. These procedures ...
full textMy Resources
Save resource for easier access later
Journal title:
acta medica iranicaجلد ۵۱، شماره ۴، صفحات ۲۰۹-۲۱۴
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023